医学
肥大细胞
伊马替尼
哮喘
酪氨酸激酶
临床试验
安慰剂
免疫学
肿瘤科
内科学
病理
受体
替代医学
髓系白血病
摘要
Mast cells and many of their secreted products have long been thought to contribute to the pathologic processes underlying asthma,1,2 but no clinical studies have assessed whether specifically targeting mast-cell survival or development would have therapeutic benefit in the treatment of this disorder. In this issue of the Journal, Cahill and colleagues3 report the results of a randomized, double-blind, placebo-controlled, phase 2, 24-week, proof-of-principle trial in which patients with severe, poorly controlled asthma were treated with the tyrosine kinase inhibitor imatinib, which can inhibit KIT,4 the major survival and growth factor for mast cells.2 The total number of patients . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI